VBI Vaccines Advances Glioblastoma Cancer Vaccine with “Incredibly Encouraging” New Data

Biopharmaceutical company, VBI Vaccines Inc. (Nasdaq: VBIV) has announced new interim tumor response data from its Phase 2b study of VBI-1901, the company’s cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients. The company’s share price rose almost 10% in trading on Wednesday following the news, and rose an additional 3.37% in morning trading on Thursday.

12,000 new cases of glioblastoma are diagnosed in the US each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and has a high mortality. The FDA has granted VBI-1901 Fast Track Designation and Orphan Drug Designation for the treatment of RGBM.

David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, said, “The tumor responses we have seen to date are incredibly encouraging, and, like the tumor responses did in the Phase 1/2a study, I am excited to see how this translates to clinical and survival outcomes later this year. The approved treatments for recurrent GBM patients have limited to no efficacy, which is consistent with the data seen in the standard-of-care arm in this study. VBI-1901’s ability to stimulate an immune response capable of generating a disease control rate of 43% at this interim stage of the study, including a partial response, is hopefully an indication of the potential of this candidate to make a meaningful difference in the lives of patients, providers, and families.”

Among the 7 evaluable patients, one partial tumor response (PR) and two stable disease (SD) observations had occurred as of May 15, 2024. The partial response, which demonstrated a 67% reduction in tumor size versus baseline, was observed at week 6, after 2 doses of VBI-1901.

VBI’s data will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 1, 2024.

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology and a proprietary mRNA-launched eVLP (“MLE”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/
News and Resources: http://www.vbivaccines.com/news-and-resources/
Investors: http://www.vbivaccines.com/investors/